

William Bains

Short CV

After a first degree at Oxford, PhD at Warwick and Postdoc at Stanford, California, William held a lectureship at University of Bath, researching *inter alia* genomics and bioinformatics technologies. In 1988 he joined PA Consulting Group, and in October 1996 he joined Merlin Ventures, a specialist bioscience investment group where he wrote the business plans for Ark Therapeutics among others. In 1999 William founded his first start-up biotech company, Amedis Pharmaceuticals Ltd, which he took from concept through three funding rounds to an established company with two technology platforms, a major Pharmaceutical collaboration and product development programmes. Since leaving Amedis William has been a founder of a further four biotech companies, is a Board member of several others and was a founding trustee of the Biogerontology Research Foundation. He also teaches entrepreneurship and company creation Cambridge University, and conducts research in entrepreneurship and company financing, as well as a variety of biomedical topics and drug discovery..

William's expertise has been recognised with Toshiba Year of Invention prize in 1992, election to Human Genome Organisation in 1994, appointment as a visiting Professor at Imperial College, London in 1999, and visiting fellow of Caius College and associate faculty, University of Cambridge 2006. He is author of numerous papers and patents and four books, and is editor-in-chief of *Bioscience Hypotheses*, an Elsevier journal that publishes innovative new ideas, theories and speculations in the life sciences and technologies.

Books:

- Genetic Engineering for Almost Everybody. William Bains. Published Penguin Books (Pelican original) October 1987
- Artificial Intelligence from A to Z. Jenny Raggett and William Bains. Published by Chapman and Hall, Autumn 1991
- Biotechnology from A to Z. William Bains, Introduction by G. Kirk Rabb. Published by Oxford University Press, April 1993: 2nd edition 1998, 3rd edition (2004)
- Venture Capital and the European Biotechnology Industry. William Bains. Published by Palgrave Macmillan, November 2008.

Selected papers

- The Biomedical Mutual Organization: A new approach to developing new medical treatments. William Bains. *Medical Hypotheses* (2008) 70 (4): 719-723
- Small Company Mergers - good for whom? Vanessa Maybeck and William Bains. *Nature Biotechnology* 24 (11), 1343 - 1348
- What you give is what you get: investment in European biotech. William Bains, *J. Commercial Biotechnology* 12 (4): 274 - 283
- How academics can make (extra) money out of their science. William Bains. *J. Commercial Biotechnology*. 11 (4): 353 - 363
- HERG binding specificity and binding site structure: evidence from a fragment-based evolutionary computing SAR study. William Bains, Antranig Basman, Cat White (2004). *Prog. in Biophysics and Molecular Biology*. 86: 205 - 233
- Many Chemistries could be used to build living systems. William Bains (2004). *Astrobiology* 4 (2): 137 - 167
- Syntheses and pharmacological properties of the histaminic H1 antagonists sila-terfenadine-A, sila-terfenadine-B, disila-terfenadine, and sila-fexofenadine: a study on C/Si bioisosterism. Reinhold Tacke, Thomas Schmid, Martin Penka, Christian Burschka, William Bains, Julie Warneck. (2004) *Organometallics* 23 (21) 4915 - 4923
- Paradoxes of Non-Trivial Gene Networks: How Cancer-Causing Mutations Can Appear to Be Cancer-Protective. William Bains (2004) *Rejuvenation Research* 7(3): 199 - 210
- Silicon Chemistry as a novel source of chemical diversity in drug design. William Bains, Reinhold Tacke (2003). *Current Opinion in Drug Discovery and Development*. 6(4): 526 - 543
- Vasoprotective VEGF as a candidate for prevention of recurrence of fibrotic diseases such as Dupuytren's Contracture. William Bains (2003) *Medical Hypotheses* 60: 793 - 796
- Evolutionary computing methods to predict oral bioavailability QSPRs. William Bains, Richard Gilbert, Lilya Sviridenko, Jose-Miguel Gascon, Robert Scoffin, Kris Birchall, Inman Harvey, John Caldwell (2002) *Current Opinion in Drug Discovery and Development*. 5: 44-51
- Statistical mechanic prediction of non-Gompertzian ageing in extremely aged populations. William Bains (2000) *Mechanisms of Ageing and Development* 112: 89-97
- The Long-term value of genomics companies. William Bains (2000) *J. of Chemical Technology and Biotechnology*. 75: 883-900
- A spectroscopically interrogated flow-through type toxicity biosensor. William Bains (1994) *Biosens. Bioelectr.* 9: 111-117
- Hybridisation methods for DNA sequencing. William Bains (1991) *Genomics* 11: 294-301
- Similarity and divergence among rodent repetitive DNA sequences. William Bains, Kay Temple-Smith (1989) *J. Mol. Evol.* 28: 191-199
- A novel method for nucleic acid sequence determination. William Bains, Geoff C. Smith (1988) *J. Theor. Biol.* 135: 303-307
- Differential patterns of transcript accumulation during human myogenesis. Peter Gunning, Edna Hardeman, Robert Wade, Phyllis Ponte, William Bains, Helen Blau, Larry Kedes (1987) *Mol. Cell. Biol.* 7: 4100-4114

- Rate of base substitution in mammalian nuclear DNA is dependent on local sequence context. William Bains, Jane Bains (1987). *Mutat. Res.* 179: 65-74
- The multiple origins of human alu sequences. William Bains (1986) 23: 189-199
- Codon usage in histone gene families of higher eukaryotes reflects functional rather than phylogenetic relationships. Dan Wells, William Bains, Larry Kedes (1986) *J. Mol. evol.* 23: 224-241
- MULTAN: a program to align multiple DNA sequences. William Bains (1986) *Nucl. Acids Res.* 14: 159-177
- Cardiac actin is the major actin in skeletal muscle differentiation in vitro. William Bains, Phyllis Ponte, Helen Blau and Larry Kedes (1984) *Mol. Cell. Biol.* 4: 1449-1453
- Organisation and expression of cloned histone gene clusters from *Xenopus laevis* and *Xenopus borealis*. R.W.Old, H.R.Woodland, J.E.M.Ballantine, T.C.Aldridge, C.A.Newton, W.A.Bains, P.C.Turner (1982) *Nucl. Acids Res.* 10: 7561-7580